With every woman, with ou dedicated breast

You are not alone Breast cancer is affecting the lives of millions of women and their families. Its personal and community impacts are very important, and major efforts are being devoted worldwide to its early detection and effective treatment. Breast cancer is better known today than ever before, far beyond its earlier classification in “lobular” or “ductal” or purely by size. Every woman can now have the better opportunity each one of them deserves, by clearly differentiating benign from malignant lesions, avoiding overdiagnosis and unnecessary treatments, accurately identifying tumor types,...

Imaging to the rescue Being able to SEE breast cancer with ever increasing accuracy is a cornerstone of its effective diagnosis and treatment. A host of clinical ways and technologies are being applied today, from the basic self-exploration or x-ray screening, improved by digital or tomosynthesis options, to sophisticated stereotactic prone tables or the advanced MRI programs for high risk groups and staging. Each one of them has clinical and economic pros and cons. Dedicated breast PET is fast emerging as a solid, proven, reliable and cost- effective multistage imaging alternative. Primary detection...

Molecular Vision: A View to Cure Standard breast imaging alternatives (X ray mammography, tomosynthesis, ultrasound...) and even CT or MRI are, providing often high resolution ANATOMICAL information. Important challenges are that changes detected (microcalcifications, shapes and shadows...) are compared with images of “normal” anatomy, and that these changes evolve at a different rate than the tumor itself. While anatomical imaging is indeed very valuable, FUNCTIONAL (MOLECULAR) imaging is providing a DECISIVE view: what the tumor does, its metabolism, areas of biggest and lowest activity Mammi...

Mammi: top SEVEN clinical advantages 1 Whole breast TRUE 3D images, with very precise quantification of tumor activity - ecisive for assessing the real size and shape of the tumor and its possible heterogeneous D or multicentric character. - Accurate and VERY early visual confirmation and measurement of efficacy of QT/ HT / RT. - Crystal clear guidance for surgery, even in dense breasts. 2 atural prone position, no breast compression for improved sensitivity and optimum N patient comfort - mproved detection of “difficult” lesions: near thoracic wall, small breasts, multicentric, I heterogeneous,...

Mammi´s top five clinical indications. Fast, accurate assessment of primary systemic (neoadjuvant) therapy chemotherapy, hormonotherapy, radiotheraphy Keys are high resolution and very accurate quantification of tumor activity - Proven, actionable results in three weeks vs three+ cycles (three+ months). BEFORE surgery -also even after partial excisions- diverse therapies are contributing to improve healing for more and more women with breast cancer. These treatments are targeting different tumor fenotypes, and assessing their success as early as possible is critical for optimizing personalized...

With every woman, with ou The Long Designed with it. and the Short of women in mind Very early diagnosis of breast cancer in women from complex or high risk groups In spite of improved therapies, early diagnosis and accurate tumor identification are the keystones for defeating breast cancer. Women´s physiology and evolution and limitations in sensitivity and specificity in existing clinical ways are not a barrier for dbPET Mammi, with its unique capacity for individualizing tumor types by true shape and dynamic metabolic activity. Often complementary of other techniques, its unprecedented accuracy...

Early breast cancer and non-malignant lesions diagnosis Normal breast Normal breast Basal tumor. Ring architecure, bed design and no compression of the breast are permitting visualization of tumors very close to the chest wall High clinical resolution. Detection of tumors half a grain of rice in size. Precise stratification of multifocal tumors

With every woman, with ou The REAL shape of heterogeneous tumors Accurate quantification of tumor activity and SuV Area: 0.954 cm2 Mean: 0.214 Max: 0.687 FDG dbPET excels at measuring the real metabolic activity of (even every region in) a tumor, assessing its agressiveness with unprecedented precision, high sensitivity, 1,4 mm clinical resolution. Advanced, easy to use software tools optimize tumor characterization and treatment efficacy assessment. Revolutionary: measuring results of primary systemic (neoadjuvant) theraphy Very fast and accurate evaluation of the results of therapies in 95%+...

Mammi, the best clinical a New technology has to prove its clinical and economic advantages, as well as fitting in the latest algorithms of care. Mammi is adding a qualitative, significantly different, cost effective type of information to previous options, of which is often complementary. Repeated experience is showing that, after a secondary exploration with Mammi, previously undetected lesions in the primary modality can now be confirmed. The true shape and activity of even the different regions of each tumor is now, at last, visible, and can accurately be measured, before and after therapies....

al and economic decision dbPET Mammi and whole body (WB) PET Whole Body PET is an excellent functional exploration, specially valuable for assessing distant extensions of the original tumor. In spite of recent progress, its resolution (often nearing 7 mm) is still not adequate for primary detection or quick assessment of therapy local breast results. The significantly improved resolution, precision quantification, very low dose (1/3 to 1/4) allowing safer repeated explorations in younger women, very fast explorations and interpretation and the flexibility added by liberating WB PET for other...

With every woman, with ou Beyond FDG New tracers, revolutionary options for PERSONALIZED breast diagnosis and integral assessment Courtesy of Dr. Valdés Olmos, ICRIDI, NKI Amsterdam Spain address: Centro de Investigación Príncipe Felipe (CIPF) Eduardo Primo Yúfera, 3 46013 Valencia SPAIN Phone: +34 963 722 472 USA address: Oncovision Inc. 44 School Street – Suite 250 Boston, MA 02108 USA Phone: (617) 505-1464